Work productivity in patients with axial spondyloarthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review and meta-analysis
Rudwaleit M, Morup M, Humphries B, Zannat N-E, Willems D, Taieb V, Boonen A (2023)
RMD Open 9(4): e003468.
Zeitschriftenaufsatz
| Veröffentlicht | Englisch
Download
e003468.full.pdf
1.84 MB
Autor*in
Rudwaleit, MartinUniBi;
Morup, Michael;
Humphries, Brittany;
Zannat, Noor-E;
Willems, Damon;
Taieb, Vanessa;
Boonen, Annelies
Einrichtung
Abstract / Bemerkung
BackgroundAxial spondyloarthritis (axSpA) can limit work participation. Our objective was to characterise productivity in patients with axSpA, including changes after 12-16 weeks of treatment with biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs).MethodsA systematic literature review identified studies published from 1 January 2010 to 21 October 2021 reporting work productivity using the Work Productivity and Activity Impairment (WPAI) questionnaire in patients with axSpA initiating b/tsDMARDs. Baseline and Week 12-16 overall work productivity, absenteeism, presenteeism and activity impairment scores were used in a random-effects meta-analysis to calculate absolute mean change from baseline for each WPAI-domain.ResultsEleven studies in patients with axSpA who received either placebo (n=727) or treatment with adalimumab, bimekizumab, etanercept, ixekizumab, secukinumab or tofacitinib (n=994) were included. In working patients initiating a b/tsDMARD, mean baseline overall work productivity impairment, absenteeism and presenteeism scores were 52.1% (N=7 studies), 11.0% and 48.8% (N=6 studies), respectively. At Week 12-16, the pooled mean change from baseline in overall work impairment for b/tsDMARDs or placebo was -21.6% and -12.3%. When results were extrapolated to 1 year, the potential annual reductions in cost of paid and unpaid productivity loss per patient ranged from euro11 962.88 to euro14 293.54.ConclusionsOver 50% of employed patients with active axSpA experienced work impairment, primarily due to presenteeism. Overall work productivity improved at Weeks 12-16 to a greater extent for patients who received b/tsDMARDs than placebo. Work productivity loss was associated with a substantial cost burden, which was reduced with improvements in impairment.
Stichworte
Outcome Assessment;
Health Care;
Patient Reported Outcome Measures;
Spondylitis;
Ankylosing;
Antirheumatic Agents;
Inflammation
Erscheinungsjahr
2023
Zeitschriftentitel
RMD Open
Band
9
Ausgabe
4
Art.-Nr.
e003468
Urheberrecht / Lizenzen
eISSN
2056-5933
Page URI
https://pub.uni-bielefeld.de/record/2985913
Zitieren
Rudwaleit M, Morup M, Humphries B, et al. Work productivity in patients with axial spondyloarthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review and meta-analysis. RMD Open. 2023;9(4): e003468.
Rudwaleit, M., Morup, M., Humphries, B., Zannat, N. - E., Willems, D., Taieb, V., & Boonen, A. (2023). Work productivity in patients with axial spondyloarthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review and meta-analysis. RMD Open, 9(4), e003468. https://doi.org/10.1136/rmdopen-2023-003468
Rudwaleit, Martin, Morup, Michael, Humphries, Brittany, Zannat, Noor-E, Willems, Damon, Taieb, Vanessa, and Boonen, Annelies. 2023. “Work productivity in patients with axial spondyloarthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review and meta-analysis”. RMD Open 9 (4): e003468.
Rudwaleit, M., Morup, M., Humphries, B., Zannat, N. - E., Willems, D., Taieb, V., and Boonen, A. (2023). Work productivity in patients with axial spondyloarthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review and meta-analysis. RMD Open 9:e003468.
Rudwaleit, M., et al., 2023. Work productivity in patients with axial spondyloarthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review and meta-analysis. RMD Open, 9(4): e003468.
M. Rudwaleit, et al., “Work productivity in patients with axial spondyloarthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review and meta-analysis”, RMD Open, vol. 9, 2023, : e003468.
Rudwaleit, M., Morup, M., Humphries, B., Zannat, N.-E., Willems, D., Taieb, V., Boonen, A.: Work productivity in patients with axial spondyloarthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review and meta-analysis. RMD Open. 9, : e003468 (2023).
Rudwaleit, Martin, Morup, Michael, Humphries, Brittany, Zannat, Noor-E, Willems, Damon, Taieb, Vanessa, and Boonen, Annelies. “Work productivity in patients with axial spondyloarthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review and meta-analysis”. RMD Open 9.4 (2023): e003468.
Alle Dateien verfügbar unter der/den folgenden Lizenz(en):
Creative Commons Namensnennung-Nicht kommerziell 4.0 International (CC BY-NC 4.0):
Volltext(e)
Name
e003468.full.pdf
1.84 MB
Access Level
Open Access
Zuletzt Hochgeladen
2024-03-18T13:24:43Z
MD5 Prüfsumme
8703013ab7ab0decaf5af8705533422f
Link(s) zu Volltext(en)
Access Level
Open Access
Export
Markieren/ Markierung löschen
Markierte Publikationen
Web of Science
Dieser Datensatz im Web of Science®Quellen
PMID: 38035757
PubMed | Europe PMC
Suchen in